9O63
 
 | | Crystal structure of PLK4 and RP1664 complex | | Descriptor: | 5-cyclopropyl-N~2~-[2,6-difluoro-4-(methanesulfonyl)phenyl]-N~2~-methyl-6-(1-methyl-1H-imidazol-4-yl)-N~4~-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine, SULFATE ION, Serine/threonine-protein kinase PLK4 | | Authors: | Pau, V.P.T, Mao, D.Y.L, Mader, P, Maderova, Z, Zimmermann, M, Sicheri, F. | | Deposit date: | 2025-04-11 | | Release date: | 2025-05-28 | | Method: | X-RAY DIFFRACTION (2.26 Å) | | Cite: | Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor.
J.Med.Chem., 2025
|
|
